Answers are grounded in this paper and cite their sources.
Melanoma heterogeneity and phenotypic plasticity remain major barriers to durable therapeutic responses. Although immune checkpoint blockade and MAPK-targeted therapies have substantially improved patient outcomes, primary and acquired resistance continue to limit long-term disease control. This has intensified efforts to identify molecular regulators that support tumor adaptation and may provide new therapeutic vulnerabilities. The review discusses mechanisms of therapeutic resistance in melanoma, current treatment limitations, and emerging molecular vulnerabilities. Within this landscape, RIPK4 has emerged as a context-dependent regulator of melanoma progression and therapeutic response. Experimental and clinical studies associate RIPK4 with tumor growth, invasion and metastatic behavior, while functional analyses link its activity to NF-κB, Wnt/β-catenin, FAK/AKT and MAPK-associated signaling. RIPK4 also influences responses to therapeutic stress with reported effects on ABCG2 abundance and survival-associated signaling, and its depletion can enhance melanoma sensitivity to BRAF inhibition, cytotoxic agents, vitamin D and melatonin. These findings support RIPK4 as a potential therapeutic vulnerability in melanoma, although its therapeutic potential remains to be established. Future studies should define the molecular determinants of RIPK4 dependency and develop selective inhibitors that distinguish kinase-dependent from non-catalytic functions.
No takes yet. Share an insight, caveat, or question.
Madej et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: